Results 151 to 160 of about 9,174 (251)
Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy
Allergy, EarlyView.We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,Musa R. Khaitov, Maria G. Byazrova, Evgenii V. Smolnikov, Vladislav N. Turenko, Valeriy V. Smirnov, Igor P. Shilovskii, Nadezhda N. Shershakova, Ekaterina N. Medunitsyna, Olga G. Elisyutina, Mikhail V. Pashenkov, George B. Pasikhov, Vladimir V. Murugin, Veronika A. Parshina, Darya K. Bolyakina, Anastasia S. Primak, Mariya A. Lapyko, Inna V. Danilycheva, Rosalia V. Schubelko, Anastasia A. Tsyvkina, Nataliia V. Shartanova, Daria O. Timoshenko, Irina I. Isakova, Tatiana V. Latysheva, Andrey E. Shulzhenko, Elena A. Latysheva, Oksana M. Kurbacheva, Elena S. Fedenko, Oksana A. Markova, Ilya A. Korotkevich, Violetta V. Yan, Natalia A. Gavrilova, Mariia V. Tikhomirova, Ivan V. Shevchenko, Alena A. Agafonova, Gregory N. Poroshin, Dmitry A. Kudlay, Alexander V. Filatov, Evgeniya V. Nazarova, Daria S. Kruchko, Dmitriy V. Goryachev, Vadim A. Merkulov, Nataliya I. Ilina, Rudolf Valenta, Veronica I. Skvortsova +43 morewiley +1 more sourceAs‐Needed Versus Regular Medication Use in the Treatment of Allergic Rhinitis in the Pollen Season: A MASK‐air Study
Allergy, EarlyView.Using MASK‐air app data from 1042 users across 2690 weeks, this study compared the impact of regular versus as‐needed allergic rhinitis medication on symptom control and treatment satisfaction. Mixed‐effects linear regression models and sensitivity analyses revealed no significant differences between the two approaches, with results for oral ...Bernardo Sousa‐Pinto, Rafael José Vieira, Antonio Bognanni, Ludger Klimek, Ana Margarida Pereira, Rita Amaral, Anna Bedbrook, Patrizia Bonadonna, Luisa Brussino, Mark S. Dykewicz, Mattia Giovannini, Bilun Gemicioglu, Juan Carlos Ivancevich, Violeta Kvedariene, Manuel Marques‐Cruz, Matteo Martini, André Moreira, Marek Niedoszytko, Michal Ordak, Nikolaos G. Papadopoulos, Oliver Pfaar, Nhân Pham‐Thi, Orathai Jirapongsananuruk, Frederico S. Regateiro, Sanna K. Toppila‐Salmi, Joaquin Sastre, Luís Taborda‐Barata, Ilgım Vardaloğlu Koyuncu, Arunas Valiulis, Maria Teresa Ventura, Kangsadarn Tanjararak, Yi‐Kui Xiang, Mohamed H. Shamji, Maria José Torres, Holger J. Schünemann, Danilo di Bona, João A. Fonseca, Torsten Zuberbier, Jean Bousquet +38 morewiley +1 more sourceUnderstanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases
Allergy, EarlyView.ABSTRACT
Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis +22 morewiley +1 more sourceEfficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy
Allergy, EarlyView.In this Phase 2a trial, severely peanut‐allergic participants were randomized to abatacept versus placebo with peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. No significant difference was observed for the primary efficacy outcome (the relative change from baseline in peanut‐specific/total IgE ratio at 24 weeks), but ...Marie‐Lee Simard, Camille Braun, Éloise Antony, Émilie Roy, Marie‐Ève Gingras, François Graham, Anne Des Roches, Louis Paradis, Kathryn Samaan, Florence Gingras‐Lessard, Roxane Labrosse, Thomas Eiwegger, Philippe Bégin +12 morewiley +1 more sourceThe Impact of Common Medications on Male Fertility: An Updated Systematic Review
Andrology, EarlyView.ABSTRACT Background
Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin +7 morewiley +1 more sourceDupilumab in Cholinergic Urticaria: An Exploratory Phase 2 Investigator‐Initiated Study
Allergy, EarlyView.Annika Gutsche, Weronika Grabowska, Sabine Altrichter, Eva Grekowitz, Stephanie Roll, Guido Heine, Petra Staubach, Wolfgang Pfützner, Randolf Brehler, Andrea Bauer, Nicola Wagner, Gerda Wurpts, Pascale Salameh, Ali Salehzadeh‐Yazdi, Samad S. Jahandideh, Martin Metz +15 morewiley +1 more sourceDry eye disease symptoms and associated risk factors in a Norwegian clinical cohort
Acta Ophthalmologica, EarlyView.Abstract Background
The relationship between dry eye disease (DED) symptoms and different demographic, clinical and lifestyle factors remains poorly understood. Norway's cold climate and dry indoor air may accelerate tear evaporation, contributing to a very high meibomian gland dysfunction prevalence, as found in multiple studies.Mazyar Yazdani, Fredrik A. Fineide, Reza A. Badian, Ayyad Zartasht Khan, Helge Rootwelt, Jan Terje Kvaløy, Tor Paaske Utheim +6 morewiley +1 more sourceFactors Associated With Omalizumab Response in Chronic Spontaneous Urticaria: Are There Age‐Related Differences?
Acta Paediatrica, EarlyView.ABSTRACT Aim
This study aimed to explore clinical and laboratory markers of omalizumab response in paediatric and adult chronic spontaneous urticaria (CSU) patients. Methods
The study included 32 children and 67 adults with CSU receiving omalizumab, and 29 paediatric and 30 adult healthy controls; associations with treatment response were evaluated ...Güler Yıldırım Nalbant, Raif Coşkun, Nilay Çalışkan, Merve Karaca Şahin, Aslı Berivan Topçak, Muhammed Fatih Erbay, Çağla Öztürk Turan, Hilal Güngör, Hamit Boloğur, Hasan Tunç Şarman, Şule Papağan, Ömer Yılmaz Ulutaş, Şefika İlknur Kökçü Karadağ, Özlem Terzi, Deniz Özçeker +14 morewiley +1 more sourceA phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial
British Journal of Haematology, EarlyView.The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...Matthew J. Ahearne, Matthew A. Timmins, Charlotte Gaskell, Aimee Jackson, Clare Morland, Sonia Fox, Louise Hopkins, Nadia Nawaz, Susann Lehmann, Marc Wadsley, Caroline Cowley, Jacqueline Shaw, Naeem Khan, Nagesh Kalakonda, Christopher Trethewey, Ram Malladi, Paul Fields, Dima El Sharkawi, Michael Quinn, Nimish Shah, Andrew Davies, Kim Linton, Pam McKay, Rod Johnson, Simon D. Wagner, David Lewis, Graham P. Collins, Christopher P. Fox, Kate Cwynarski +28 morewiley +1 more source